Side-by-side · Research reference
BPC-157vsCJC-1295 (no DAC)
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed9/53 cited
BPhase 1Reviewed15/51 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
CJC-1295 (no DAC)
Short-acting GHRH · No DAC variant
SQ · Pre-sleep · 1–2×/day
01Mechanism of Action
Parameter
BPC-157
CJC-1295 (no DAC)
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014Sikiric 2018
Pituitary GHRH receptorTeichman 2006
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Yes — short pulse preserves somatostatin negative feedbackIonescu 2006
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006
Antibody development
—
Not reported in short-term studies
02Dosage Protocols
Parameter
BPC-157
CJC-1295 (no DAC)
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
100 mcg per injectionTeichman 2006
Often paired with ipamorelin in same syringe.
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
1–2× daily (pre-sleep ± morning)
Lower / starter dose
200 mcg / day
Conservative starter for new users.
50 mcg per dose
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006Ionescu 2006
No-DAC variant is less studied directly; PK extrapolated from native GHRH.
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
8–12 weeks on / 4 off (anecdotal)
Reconstitution
Bacteriostatic water, 1–2 mL
Bacteriostatic water
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
Pre-sleep + fasted preferred
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
~30 minIonescu 2006
Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.
04Side Effects & Safety
Parameter
BPC-157
CJC-1295 (no DAC)
Injection site reaction
Mild irritation (anecdotal)
Erythema, mild pruritus
GI symptoms
None reported in PL-14736 Phase 2
—
Cardiovascular
Not reported
—
Cancer risk
Theoretical concern via VEGF angiogenesis pathwaySikiric 2018
Contraindicated in active malignancy (GH/IGF-1 axis)
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
Avoid
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Flushing / headache
—
Common transient effect
Cortisol elevation
—
Minimal at standard doses
Prolactin elevation
—
Minimal
Glucose intolerance
—
Possible at high cumulative doses
IGF-1 elevation
—
Dose-dependent; monitor with chronic use
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
CJC-1295 (no DAC)
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
CJC-1295 (no DAC)
- ·Untreated diabetes
- ·Severe insulin resistance
05Administration Protocol
Parameter
BPC-157
CJC-1295 (no DAC)
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
Subcutaneous, abdomen or thigh. Rotate sites.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Pre-sleep preferred. Often combined with ipamorelin in the same syringe.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
CJC-1295 (no DAC)
+ Ipamorelin
StrongCJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.
- CJC-1295 (no DAC)
- 100 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition